Sagimet Biosciences (STU:0O2) Current Accrued Expense: €2.54 Mil (As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.14
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Current Accrued Expense?

Sagimet Biosciences STU:0O2 +1.66% 10 Current Accrued Expense is €2.54 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Sagimet Biosciences's Current Accrued Expense for the quarter that ended in Mar. 2026 was €2.54 Mil.

Sagimet Biosciences's quarterly Current Accrued Expense declined from Sep. 2025 (€4.07 Mil) to Dec. 2025 (€3.15 Mil) and declined from Dec. 2025 (€3.15 Mil) to Mar. 2026 (€2.54 Mil).

Sagimet Biosciences's annual Current Accrued Expense declined from Dec. 2023 (€4.74 Mil) to Dec. 2024 (€2.81 Mil) but then increased from Dec. 2024 (€2.81 Mil) to Dec. 2025 (€3.15 Mil).

Sagimet Biosciences Current Accrued Expense Related Terms

Sagimet Biosciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Current Accrued Expense Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 1.21 3.74 4.74 2.81 3.15

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.61 4.48 4.07 3.15 2.54
STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €2.54 Mil mean?
Sagimet Biosciences (STU:0O2) has a Current Accrued Expense of €2.54 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Current Accrued Expense too high?
Sagimet Biosciences' current Current Accrued Expense is €2.54 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Current Accrued Expense compare to NGNE and UPB?
Sagimet Biosciences' Current Accrued Expense of €2.54 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Current Accrued Expense is €2.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Current Accrued Expense of €2.54 Mil. The current Current Accrued Expense is €2.54 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Current Accrued Expense is €2.54 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14
Price